CD44 Targeting of Cisplatin-Loaded Hyaluronic Acid-Modified Mesoporous Silica Nanoparticles for Lung Adenocarcinoma: Synthesis, Characterization, In Vitro and In Vivo Evaluation

Basit Öğe Kaydı
dc.authoridhttps://orcid.org/0000-0003-4945-4794
dc.authoridhttps://orcid.org/0000-0002-0373-0602
dc.authoridhttps://orcid.org/0000-0002-0525-9690
dc.authoridhttps://orcid.org/0000-0002-3759-6616
dc.authoridhttps://orcid.org/0000-0003-3295-3538
dc.authoridhttps://orcid.org/0000-0003-4227-1637
dc.authoridhttps://orcid.org/0000-0002-7954-1381
dc.authoridhttps://orcid.org/0000-0002-7483-0184
dc.contributor.authorGüler, Cem
dc.contributor.authorGelen, S. Sacide
dc.contributor.authorŞancı, Ebru
dc.contributor.authorBuhur, Aylin
dc.contributor.authorTıkır, H. Ece
dc.contributor.authorNalbantsoy, Ayşe
dc.contributor.authorGüner, Adem
dc.contributor.authorMedine, E. İlker
dc.contributor.authorYavaşoğlu, Altuğ
dc.contributor.authorOdacı, Dilek
dc.contributor.authorYavaşoğlu, N. Ülkü Karabay
dc.date.accessioned2026-03-05T11:08:30Z
dc.date.available2026-03-05T11:08:30Z
dc.date.issued2026
dc.departmentFakülteler, Diş Hekimliği Fakültesi, Temel Bilimler Bölümü
dc.description.abstractBackground/Objectives: Cisplatin (CDDP) is widely used in the treatment of non-small cell lung cancer (NSCLC); however, its clinical efficacy is limited by severe systemic toxicity. Hyaluronic acid (HA) modification enables the targeting of CD44-overexpressing cancer cells, enhances biocompatibility, provides controlled drug release, and prolongs systemic circulation. This study aimed to develop high-molecular-weight hyaluronic acid-modified, cisplatin-loaded mesoporous silica nanoparticles (HA-MSN-CDDP) to selectively target CD44- overexpressing lung adenocarcinoma cells. Methods: HA-MSN-CDDP nanoparticles were synthesized via the sol–gel method and characterized by FTIR, DLS, SEM, and TEM methods. Antitumor efficacy was evaluated using both in vitro and in vivo xenograft lung cancer models in mice. Results: HA modification enabled controlled and sustained release of cisplatin from the HA-MSN-CDDP drug delivery system. Through HA-mediated receptor-dependent endocytosis, the nanoparticles exhibited enhanced cellular uptake and selective cytotoxicity toward CD44-positive cells. HA-MSN-CDDP significantly reduced the cytotoxic, genotoxic, and oxidative stress effects of free cisplatin on healthy cells while markedly enhancing apoptosis in A549-Luc-C8 cells. The system showed excellent hemocompatibility, supporting its potential for intravenous use. In vivo, HA-MSN-CDDP effectively suppressed tumor growth, mitigated lipid peroxidation, and preserved antioxidant enzyme activities (SOD and CAT) in major organs. Histological analyses confirmed reduced cisplatin-induced nephrotoxicity. Conclusions: HA-MSN-CDDP demonstrates strong potential as a targeted chemotherapeutic platform for NSCLC, combining high antitumor efficacy with reduced systemic toxicity
dc.identifier.citationGüler, C., Gelen, S. S., Şancı, E., Buhur, A., Tıkır, H. E., Nalbantsoy, A., Güner, A., Medine, E. İ., Yavaşoğlu, A., Odacı, D., & Karabay Yavaşoğlu, N. Ü. (2026). CD44 targeting of cisplatin-loaded hyaluronic acid-modified mesoporous silica nanoparticles for lung adenocarcinoma: Synthesis, characterization, in vitro and in vivo evaluation. Pharmaceutics, 18(2), 171. https://doi.org/10.3390/pharmaceutics18020171
dc.identifier.doi10.3390/pharmaceutics18020171
dc.identifier.endpage26
dc.identifier.issue2
dc.identifier.pmid41754914
dc.identifier.startpage2
dc.identifier.urihttps://hdl.handle.net/20.500.12941/388
dc.identifier.volume18
dc.indekslendigikaynakPubMed
dc.institutionauthorBuhur, Aylin
dc.institutionauthoridhttps://orcid.org/0000-0002-3759-6616
dc.language.isoen
dc.relation.ispartofPharmaceutics
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectCisplatin
dc.subjectMesoporous Silica Nanoparticles
dc.subjectHyaluronic Acid
dc.subjectCD44
dc.subjectDrug Delivery System
dc.subjectActive Targeting
dc.subjectLung Cancer
dc.titleCD44 Targeting of Cisplatin-Loaded Hyaluronic Acid-Modified Mesoporous Silica Nanoparticles for Lung Adenocarcinoma: Synthesis, Characterization, In Vitro and In Vivo Evaluation
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
pharmaceutics-18-00171.pdf
Boyut:
6.45 MB
Biçim:
Adobe Portable Document Format
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.17 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Temel Bilimler Bölümü Koleksiyonu